Cornelissen R et al. Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER-2 exon 20 mutations: A multinational phase 2 study (ZENITH20-4). ESMO 2021;Abstract LBA46.
Elamin YY et al. Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: Results from a phase II trial. J Clin Oncol 2022;40(7):702-9. Abstract
Goto K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 mutant metastatic non-small-cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.
Han H et al. Targeting HER2 exon 20 insertion-mutant lung adenocarcinoma with a novel tyrosine kinase inhibitor mobocertinib. Cancer Res 2021;81(20):5311-24. Abstract
Kris MG et al. Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 2015;26(7):1421-7. Abstract
Lai WV et al. Afatinib in patients with metastatic ore recurrent HER2-mutant lung cancers: A retrospective international multicentre study. Eur J Cancer 2019;109:28-35. Abstract
Le X et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J Clin Oncol 2022;40(7):710-18. Abstract
Li BT et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov 2020;10(5):674-87. Abstract
Li BT et al. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. ASCO 2022;Abstract 102.
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Mazieres J et al. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: Results from the IFCT-1703 R2D2 trial. J Clin Oncol 2022;40(7):719-28. Abstract
Planchard D. ESMO e-learning: Rare oncogenic alterations in NSCLC. ESMO E-Learning and V-Learning 2022;Abstract.
Ren S et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open Cancer Horizons 2022;7(1):100395. Abstract
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40(6):611-25. Abstract
Yu X et al. HER2-altered non-small cell lung cancer: Biology, clinicopathologic features, and emerging therapies. Front Oncol 2022;12:860313. Abstract